C. Baccei

发表

In vitro and in vivo pharmacology of NXT629, a novel and selective PPAR&agr; antagonist☆

D. Lorrain, P. Prasit, D. Messmer, 2017, European journal of pharmacology.

Pharmacological Characterization of 3-[3-tert-Butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic Acid (AM103), a Novel Selective 5-Lipoxygenase-Activating Protein Inhibitor That Reduces Acute and Chronic Inflammation

Jilly F. Evans, D. Lorrain, C. King, 2009, Journal of Pharmacology and Experimental Therapeutics.

Pharmacological Blockade of the DP2 Receptor Inhibits Cigarette Smoke-Induced Inflammation, Mucus Cell Metaplasia, and Epithelial Hyperplasia in the Mouse Lung

Jilly F. Evans, D. Lorrain, P. Prasit, 2010, Journal of Pharmacology and Experimental Therapeutics.

5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor.

Jilly F. Evans, D. Lorrain, P. Prasit, 2011, Journal of medicinal chemistry.

Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammation.

Jilly F. Evans, D. Lorrain, P. Prasit, 2010, European journal of pharmacology.

5-Lipoxygenase-activating protein inhibitors. Part 3: 3-{3-tert-Butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM643)-A potent FLAP inhibitor suitable for topical administration.

Jilly F. Evans, D. Lorrain, P. Prasit, 2010, Bioorganic & medicinal chemistry letters.

5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)--a potent FLAP inhibitor.

Jilly F. Evans, D. Lorrain, P. Prasit, 2010, Bioorganic & medicinal chemistry letters.

5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103).

Jilly F. Evans, D. Lorrain, P. Prasit, 2009, Journal of medicinal chemistry.

Pharmacokinetic and Pharmacodynamic Characterization of an Oral Lysophosphatidic Acid Type 1 Receptor-Selective Antagonist

Jilly F. Evans, D. Lorrain, P. Prasit, 2011, Journal of Pharmacology and Experimental Therapeutics.

Discovery and optimization of a biphenylacetic acid series of prostaglandin D2 receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis.

Jilly F. Evans, D. Lorrain, P. Prasit, 2011, Bioorganic & medicinal chemistry letters.

Pharmacology of AM211, a Potent and Selective Prostaglandin D2 Receptor Type 2 Antagonist That Is Active in Animal Models of Allergic Inflammation

Jilly F. Evans, D. Lorrain, P. Prasit, 2011, Journal of Pharmacology and Experimental Therapeutics.

Microsoft Word-53570696-file00

D. Lorrain, P. Prasit, C. King, 2011 .

Sodium [2'-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4'-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): a potent, selective prostaglandin D2 receptor antagonist.

Jilly F. Evans, D. Lorrain, P. Prasit, 2011, Bioorganic & medicinal chemistry letters.

Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.

Jilly F. Evans, D. Lorrain, P. Prasit, 2009, Bioorganic & medicinal chemistry letters.

Group II mGlu Receptor Activation Suppresses Norepinephrine Release in the Ventral Hippocampus and Locomotor Responses to Acute Ketamine Challenge

D. Lorrain, L. Bristow, A. Pinkerton, 2003, Neuropsychopharmacology.

Discovery of potent and selective PPARα/δ dual antagonists and initial biological studies.

D. Lorrain, P. Prasit, B. Laffitte, 2019, Bioorganic & medicinal chemistry letters.

Effects of ketamine and n-methyl-d-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268

D. Lorrain, L. Bristow, M. Varney, 2003, Neuroscience.

Discovery of PIPE-359, a Brain-Penetrant, Selective M1 Receptor Antagonist with Robust Efficacy in Murine MOG-EAE.

D. Lorrain, M. M. Poon, Thomas O. Schrader, 2020, ACS medicinal chemistry letters.

A role for oleoylethanolamide in chronic lymphocytic leukemia

M. Eiden, P. Prasit, Y. Shi, 2014, Leukemia.

Phenyl-tetrazolyl acetophenones: discovery of positive allosteric potentiatiors for the metabotropic glutamate 2 receptor.

D. Lorrain, L. Bristow, A. Pinkerton, 2004, Journal of medicinal chemistry.

A novel, orally active LPA1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin model

D. Lorrain, P. Prasit, T. J. Seiders, 2010, British journal of pharmacology.

Comparison of the effects of diazepam, the CRF1 antagonist CP-154,526 and the group II mGlu receptor agonist LY379268 on stress-evoked extracellular norepinephrine levels

D. Lorrain, L. Bristow, L. Correa, 2005, Neuropharmacology.

Sodium [2'-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4'-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): a potent, selective prostaglandin D2 receptor antagonist.

Jilly F. Evans, D. Lorrain, P. Prasit, 2011, Bioorganic & medicinal chemistry letters.

Identification of the first potent, selective and bioavailable PPARα antagonist.

D. Lorrain, P. Prasit, D. Messmer, 2014, Bioorganic & medicinal chemistry letters.

Pharmacokinetic and Pharmacodynamic Characterization of an Oral Lysophosphatidic Acid Type 1 Receptor-Selective Antagonist

Jilly F. Evans, D. Lorrain, P. Prasit, 2011, Journal of Pharmacology and Experimental Therapeutics.

Identification and In Vivo Evaluation of Myelination Agent PIPE-3297, a Selective Kappa Opioid Receptor Agonist Devoid of β-Arrestin-2 Recruitment Efficacy.

D. Lorrain, K. Stebbins, A. Broadhead, 2024, ACS chemical neuroscience.

Discovery of a brain penetrant small molecule antagonist targeting LPA1 receptors to reduce neuroinflammation and promote remyelination in multiple sclerosis

D. Lorrain, K. Stebbins, A. Broadhead, 2024, Scientific reports.